Eledon Pharmaceuticals, Inc. (ELDN) Stock Analysis — Probabli.AI
AI-powered analysis for ELDN (Eledon Pharmaceuticals, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Bullish.
Last price: $3.46 · Market cap: $239.3M · AI consensus: Bullish
Eledon Pharmaceuticals appears positioned for substantial upside. Leveraging positive clinical trials, strategic funding achievements, and orphan drug upstream development provide a strong narrative for the company's potential growth. The stock is speculative but intriguing due to upside tail-risk opportunities.
Probabilistic 1-Year Outlook
- Bull 6000% · Neutral 3000% · Bear 1000%
- Eledon Pharmaceuticals has recently demonstrated positive trial results (such as for ELDN-001) and secured significant funding. Furthermore, it holds a strong analyst consensus with high implied price targets. These…
5-Year Outlook
- Bull 6500% · Neutral 2500% · Bear 1000%
SWOT Highlights
- Strength: Encouraging Phase 2 results for ELDN-001
- Strength: Recent funding boosts R&D capacity
- Risk: High average EPS negative surprise
- Risk: Clinical trial and FDA approval risks
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
2 Wall Street analysts rate ELDN a STRONG BUY with a mean price target of $8.5.
Analysis generated Apr 28, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/ELDN.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.